10-Q: Cidara Therapeutics Reports Positive CD388 Phase 2b Results

Cidara Therapeutics announced positive topline results from its Phase 2b NAVIGATE study for CD388, its influenza antiviral candidate, and reported a significantly strengthened cash position.

Summary

• Cidara Therapeutics reported a net loss of $49.2 million for the six months ended June 30, 2025, a significant improvement from the $101.5 million net loss for the same period in 2024.
• Cash, cash equivalents, and restricted cash totaled $516.9 million as of June 30, 2025, up from $196.2 million at December 31, 2024, primarily due to recent capital raises.
• The Phase 2b NAVIGATE study for CD388, evaluating pre-exposure prophylaxis of seasonal influenza, met its primary and all secondary efficacy endpoints.
• Single doses of CD388 conferred 76.1% (450mg), 61.3% (300mg), and 57.7% (150mg) protection from symptomatic influenza over 24 weeks compared to placebo (2.8% attack rate).
• CD388 was well-tolerated in the NAVIGATE study with no safety signals observed and no dose-dependent pattern in treatment-emergent adverse events.
• Research and development expenses increased to $49.4 million for the six months ended June 30, 2025, from $12.6 million in the prior year, driven by the NAVIGATE study and planned Phase 3 development.
• General and administrative expenses rose to $12.7 million for the six months ended June 30, 2025, compared to $8.3 million in the same period last year, mainly due to higher personnel and stock-based compensation costs.
• A reversal of $9.4 million in accrued indirect tax liabilities occurred during the six months ended June 30, 2025, as these amounts were determined not to be due.
• The company reacquired all rights for CD388 from Janssen in April 2024 and divested its rezafungin assets to Napp Pharmaceutical Group Limited on April 24, 2024, streamlining its focus to the Cloudbreak platform.
• An Underwritten Public Offering in June 2025 generated approximately $402.5 million in gross proceeds, contributing significantly to the increased cash balance.
• The company believes its current cash position is sufficient to fund operations through the completion of the planned Phase 3 study for CD388.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to the successful Phase 2b clinical trial results for CD388, which significantly de-risks the company's lead asset and validates its Cloudbreak platform. The substantial capital raises provide a strong financial runway through the next critical development phase. While the company remains unprofitable and faces typical biotech risks, the clinical success and strengthened liquidity are major catalysts.

Positives

• Positive topline results from the Phase 2b NAVIGATE study for CD388, demonstrating statistically significant prevention efficacy across all dose groups (76.1% at 450mg, 61.3% at 300mg, 57.7% at 150mg over 24 weeks).
• CD388 was well-tolerated in the Phase 2b study with no drug-related serious adverse events or unexpected safety signals.
• Significantly strengthened cash position with $516.9 million in cash, cash equivalents, and restricted cash as of June 30, 2025, providing liquidity through the planned Phase 3 study for CD388.
• Successful completion of a $402.5 million gross proceeds underwritten public offering in June 2025, substantially boosting capital.
• Divestment of rezafungin assets allows for a focused strategic shift to the Cloudbreak platform and CD388 development.
• Net cash used in operating activities decreased to $62.9 million for the six months ended June 30, 2025, from $110.4 million in the prior year, indicating improved operational cash burn.
• Reversal of $9.4 million in accrued indirect tax liabilities positively impacted financial results.

Negatives

• Continued significant operating losses, with a net loss of $49.2 million for the six months ended June 30, 2025.
• Increased research and development expenses to $49.4 million for the six months ended June 30, 2025, reflecting higher costs for clinical trials.
• Increased general and administrative expenses to $12.7 million for the six months ended June 30, 2025.
• Heavy dependence on the success of CD388, with other Cloudbreak product candidates (like CBO421) still in very early stages and no immediate plans for clinical trials in oncology.
• Reliance on third-party manufacturers, including a single source in China (WuXi XDC) for CD388, which poses supply chain and geopolitical risks.
• Future funding will be required beyond the planned Phase 3 study for CD388 and for commercialization efforts.

Risks

• Need for additional funding to advance CD388 beyond Phase 3 and to potentially advance other Cloudbreak programs like CBO421.
• Heavy dependence on the success of CD388, with other Cloudbreak product candidates being in very early development stages and potentially unsuccessful.
• Clinical trials for CD388 or other product candidates may be delayed, terminated, suspended, or fail to demonstrate safety and efficacy, leading to increased costs or inability to complete development and commercialization.
• Identification of serious adverse reactions or unexpected characteristics of product candidates during development may necessitate abandonment or limitation of development.
• Approved product candidates may fail to achieve sufficient market acceptance by physicians, patients, formulary committees, and third-party payors for commercial success.
• Interim, topline, and preliminary clinical trial data may change upon comprehensive review and audit, potentially resulting in material changes to final data.
• Reliance on third parties to conduct clinical trials and some aspects of research and preclinical testing, with risks of unsatisfactory performance or failure to meet deadlines.
• Lack of experience manufacturing product candidates on a clinical or commercial scale and dependence on third parties for manufacturing, which could lead to delays or impact sales.
• Inability to obtain, or delays in obtaining, required regulatory approvals would impair commercialization and revenue generation.
• Stock price volatility, which could lead to loss of investment.
• Incurrence of significant operating losses since inception and anticipation of continued substantial operating losses, with no assurance of achieving or maintaining profitability.
• Unfavorable global economic conditions, including inflation, bank failures, labor shortages, supply chain disruptions, and recession risks, could adversely affect business.
• International trade policies, including tariffs, sanctions, and trade barriers (e.g., BIOSECURE Act targeting Chinese biotechnology companies), may adversely affect business, particularly due to reliance on Chinese manufacturers.
• Lack of history in commercializing pharmaceutical products, making future viability evaluation difficult.
• Delays or difficulties in patient enrollment or mild flu seasons could delay or prevent regulatory approvals for CD388.
• Product liability lawsuits could result in substantial liabilities and limit commercialization.
• Failure to comply with environmental, health, and safety laws and regulations could lead to fines or penalties.
• Inability to establish collaborations on commercially reasonable terms could alter research, clinical development, and commercialization plans.
• Inadequate protection of intellectual property (patents, trademarks, trade secrets) could impair competitive advantage.
• Third-party claims of intellectual property infringement could prevent or delay drug development efforts.
• Issued patents could be found invalid or unenforceable if challenged.
• Changes in U.S. patent law could diminish the value of patents.
• Limited foreign intellectual property rights may hinder global protection.
• Claims that employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties.
• U.S. government audits and contract requirements, especially with additional government funding, could adversely affect business.
• System failures, cybersecurity risks, and data compromises could lead to adverse consequences.
• Operations are vulnerable to interruption by natural disasters, power loss, terrorist activity, and public health crises.
• Future success depends on ability to retain senior management and attract/retain qualified personnel.
• Difficulties in managing expected growth could disrupt business.
• Sales of substantial numbers of common stock shares by existing stockholders could cause stock price to fall.
• Future sales and issuances of common stock or rights to purchase common stock could result in additional dilution and stock price decline.
• Broad discretion in the use of working capital may not be effective.
• Anti-takeover provisions in charter documents and Delaware law could delay or prevent a change of control.
• Exclusive forum provision in bylaws could limit stockholders' ability to obtain a favorable judicial forum.
• Inaccurate or unfavorable research by securities or industry analysts could cause stock price and trading volume to decline.
• Limitations on the ability to utilize net operating loss carryforwards and certain other tax attributes.
• Uncertainties in the interpretation and application of existing, new, and proposed tax laws and regulations could materially affect tax obligations and effective tax rate.

Future Outlook

The company plans to initiate a Phase 3 study for CD388 no later than spring 2026 during the Southern Hemisphere influenza season, pending FDA consultation on the study design. It believes its existing cash, cash equivalents, and restricted cash will be sufficient to fund planned operations through the completion of this Phase 3 study. The company does not plan to initiate clinical trials for any oncology product candidates at this time, despite CBO421 receiving IND clearance.

Management Comments

• We are a biotechnology company using our proprietary Cloudbreak platform to develop drug-Fc conjugate, or DFC, therapeutics designed to save lives and improve the standard of care for patients facing serious diseases.
• Our lead clinical-stage asset is CD388, a novel long-acting antiviral which we are developing for broad spectrum influenza prophylaxis.
• We announced positive topline results in June 2025 for our 5,041-subject, randomized, double-blind, placebo-controlled Phase 2b clinical trial, or the NAVIGATE study, evaluating the efficacy and safety of CD388 for pre-exposure prophylaxis of seasonal influenza in unvaccinated healthy subjects.
• We are currently in discussions with the U.S. Food and Drug Administration, or FDA, regarding the design of a Phase 3 study for CD388, which we plan to initiate no later than in the spring of 2026 during the Southern Hemisphere influenza season, subject to FDA consultation on our study design.
• We believe our existing cash, cash equivalents and restricted cash will be sufficient to fund our planned operations through the end of our planned Phase 3 study for CD388.
• Following these transactions (CD388 reacquisition and rezafungin divestment), our sole R&D focus has now shifted to developing CD388 as a highly potent antiviral designed to deliver universal prophylaxis and treatment of seasonal and pandemic influenza.
• Our lead oncology DFC is CBO421, a development candidate targeting CD73, a key component of the adenosine pathway, for the treatment of solid tumors, which received investigational new drug application, or IND, clearance in July 2024. We do not plan to initiate clinical trials for any oncology product candidates at this time.

Industry Context

The company's strategic shift to focus solely on its Cloudbreak platform, particularly the CD388 influenza program, aligns with a trend in the biotechnology industry towards specialization and efficient resource allocation. The positive Phase 2b results for CD388 position it as a potentially transformative broad-spectrum antiviral, offering a unique approach compared to traditional vaccines and small molecule neuraminidase inhibitors like Tamiflu, Relenza, Peramivir, and endonuclease inhibitors like Xofluza. The Fast Track designation highlights the unmet medical need for influenza prevention, especially in high-risk populations. The divestment of Rezafungin, a commercially approved product, indicates a strong commitment to the DFC platform, a strategy often seen in companies aiming for high-value, innovative therapies. The significant capital raises reflect investor confidence in the CD388 program's potential, despite the inherent risks of drug development.

Comparison to Industry Standards

• The 76.1% prevention efficacy for the 450mg dose of CD388 in the NAVIGATE study compares favorably to the variable efficacy rates of traditional seasonal influenza vaccines, which typically range from 40% to 60% depending on the season and vaccine match.
• CD388's potential for single-dose, long-acting protection over 24 weeks offers a significant convenience advantage over existing daily or twice-daily oral antivirals like Tamiflu (oseltamivir) or Relenza (zanamivir), and even single-dose oral Xofluza (baloxavir marboxil), which typically offer shorter prophylactic durations.
• The observed clear dose-response for efficacy in the NAVIGATE study is a positive indicator of the drug's mechanism and predictability, a standard expectation for robust clinical development.
• The well-tolerated safety profile of CD388 with no drug-related serious adverse events is critical for a prophylactic agent, as safety expectations are higher for drugs administered to healthy or at-risk populations for prevention, similar to vaccine safety profiles.
• The company's decision to focus on CD388 and divest Rezafungin, a commercially approved product, is a bold strategic move, contrasting with companies that maintain diverse portfolios. This indicates a high conviction in the Cloudbreak platform's potential, similar to how some specialized biotech firms focus on a single, high-potential asset.
• The substantial capital raise of over $400 million in June 2025, following previous raises, demonstrates strong investor confidence, comparable to funding rounds seen in other clinical-stage biotechs with promising Phase 2 data and clear paths to pivotal trials.

Corporate Governance

Related Party Transactions

• The company reacquired all rights for CD388 from Janssen Pharmaceuticals, Inc. (an affiliate of Johnson & Johnson) on April 23, 2024, for an upfront payment of $85.0 million, effectively terminating the prior collaboration agreement.
• Sold all rezafungin assets to Napp Pharmaceutical Group Limited (an affiliate of Mundipharma Medical Company) on April 24, 2024, which included the forgiveness of an $11.1 million development milestone advance from Mundipharma.

Stakeholder Impact

• **Shareholders**: Significant dilution from recent capital raises, but also potential for increased value due to positive clinical trial results and extended cash runway. The stock price is highly volatile.
• **Employees**: Workforce reduction of 20 employees (30% of workforce) completed in November 2024, focusing resources on CD388. Stock-based compensation remains a significant component of personnel costs.
• **Customers/Patients**: Positive Phase 2b results for CD388 indicate potential for a new, effective, and convenient prophylactic treatment for influenza, addressing an unmet medical need.
• **Partners (Janssen, Napp/Mundipharma)**: Reacquisition of CD388 rights from Janssen and divestment of rezafungin to Napp/Mundipharma redefine key partnerships, allowing the company to control its lead asset fully while streamlining its portfolio.
• **Creditors**: Improved liquidity position reduces immediate credit risk, but continued operating losses indicate ongoing reliance on external financing.

Next Steps

• Submit an end of Phase 2 meeting request to the FDA to review Phase 2b results and discuss Phase 3 study design and start time for CD388.
• Initiate a Phase 3 study for CD388 no later than spring 2026 during the Southern Hemisphere influenza season, subject to FDA consultation.
• Present additional results from the NAVIGATE study at upcoming scientific conferences in 2025.
• Continue to evaluate the impact of the One Big Beautiful Bill Act (OBBBA) on financial condition and results of operations, with impacts to be included in Q3 2025 financial statements.
• Evaluate the impact of ASU 2024-03 (Income Statement Expense Disaggregation Disclosures) for adoption in fiscal years beginning after December 15, 2026.

Key Dates

Recommendation

The positive topline results from the Phase 2b NAVIGATE study for CD388 represent a significant de-risking event for Cidara Therapeutics' lead asset, validating its Cloudbreak platform and providing a clear path towards a pivotal Phase 3 trial. The high prevention efficacy and favorable safety profile are compelling. Furthermore, the substantial capital raise in June 2025, resulting in over $516 million in cash, cash equivalents, and restricted cash, provides a robust financial runway through the planned Phase 3 study, mitigating near-term liquidity concerns. The strategic divestment of the non-core rezafungin asset allows for a focused allocation of resources. While the company remains unprofitable and faces inherent risks associated with drug development and reliance on third-party manufacturing, the strong clinical data and fortified balance sheet make this an attractive entry point for investors with a long-term horizon in the biotechnology sector.

Keywords

Biotechnology, Drug-Fc Conjugate, DFC, CD388, Influenza, Antiviral, Prophylaxis, Clinical Trials, Phase 2b, NAVIGATE study, Cloudbreak platform, Biopharmaceutical, SEC Filing, 10-Q, Biotech Investment, Infectious Disease, Drug Development, Clinical Data, Capital Raise, Biotech Stocks